The present invention relates to an isolated CD31+ cell derived from adipose-derived regenerative cells (ADRC's), for use as a medicament. The invention also relates to compositions comprising such cells. In addition, the invention relates to methods for screening for the regenerative capacity of a population of adipose-derived regenerative cells (ADRC's).
|Published - 10. Oct 2019